Business
Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United States
Fiscal Q3 2025 revenue of $30.0 million, net income of $0.7 million, operating income of $3.8 mil...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"Medexus Announces Strong Fiscal Q3 2025 Results, Well-Positioned to Launch GRAFAPEX (treosulfan) for Injection in the United StatesFiscal Q3 2025 revenue of $30.0 million, net income of $0.7 million, operating income of $3.8 million, and Adjusted EBITDA* of $5.8 millionManagement to host conference call at 8:00 AM Eastern time on Thursday, February 6, 2024Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - February 5, 2025) - Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) today announced its operating and financial results and provided a business update for the company's third fiscal quarter ended December 31, 2024 (the company's fiscal Q3 2025). All dollar amounts in this press release are in United States dollars unless specified otherwise.Financial highlightsRevenue of $30.0 million and $83.6 million for the three- and nine-month periods ended December 31, 2024, an increase of $4.8 million and a decrease of $3.5 million, or 19.0% and (4.0)%, compared to $25.2 million and $87.1 million for the three- and nine-month periods ended December 31, 2023. The $4.8 million year-over-year revenue increase in fiscal Q3 2025 was attributable in part to continuing growth in net sales of Rupall and an approximately $2.0 million beneficial impact of customer buying patterns of IXINITY. The $3.5 million year-over-year revenue decrease in fiscal year 2025 to date was primarily attributable to reduced year-to-date net sales of Rasuvo and Metoject in fiscal year 2025 and declines in net sales of IXINITY since fiscal Q3 2024, partially offset by year-over-year increases in year-to-date net sales of Rupall (in Canada) and Gleolan (in both the United States and Canada).Adjusted EBITDA* of $5.8 million and $17.9 million for the three- and nine-month periods ended December 31, 2024, an increase of $2.6 million and $2.8 million, or 81.3% and 18.5%, compared to $3.2 million and $15.1 million for the three- and nine-month periods ended December 31, 2023. The $2.6 million and $2.8 million year-over-year Adjusted EBITDA* increases were primarily attributable to the effects of the Company's ongoing financial discipline efforts, together with the fiscal Q3 2025 effect of customer buying patterns mentioned above, and partially offset by the GRAFAPEX™ personnel and infrastructure investments discussed below.Available liquidity of $8.4 million ...